Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Could a Subdermal Implant Mean the End of HIV?

Findings published in Antimicrobial Agents and Chemotherapy report that a novel, subdermal implant delivering potent antiretroviral (ARV) drugs shows extreme promise in stopping the spread of HIV.

Published
12 hours ago
From
Edge San Francisco
Meet the Khayelitsha compliers club

Communities are bringing HIV monitoring and dispensing out of the clinics and into their homes.

Published
12 hours ago
From
Mail & Guardian
Adherence All-Stars

Diane Peters meets a group of PHAs with “chaotic lifestyles” and finds out how, despite major obstacles, they adhere to their meds.

Published
15 hours ago
From
CATIE
No, Teens Did Not Create a Working Condom That Changes Colors if You Have an STI, and Maybe They Shouldn’t

Last week, the story broke about teens who had invented a new condom that could detect sexually transmitted infections (STIs) and alert a partner by changing colors. But this condom-and-STI-test-wrapped-in-one is not coming soon to a pharmacy near you. It’s an interesting idea, but that’s all it is: just an idea. It’s a thought with theory behind it on how it might work. It has not gotten past the concept stage. There is no operational prototype.

Published
16 hours ago
From
RH Reality Check
NHS England announces annual investment decisions for certain specialised services [including HIV treatment as prevention]

NHS England has today (2 July) set out its planned investment decisions for certain specialised services as part of its annual commissioning round.

Published
03 July 2015
From
NHS England press release
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen that combines Gilead’s emtricitabine 200 mg and tenofovir alafenamide (TAF) 25 mg with rilpivirine 25 mg (R/F/TAF) from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the treatment of HIV-1 infection in adult and pediatric patients 12 years of age and older. The data submitted in the NDA support the use of R/F/TAF among patients who are HIV treatment-naïve or who are virologically suppressed and want to replace their current antiretroviral treatment regimen.

Published
02 July 2015
From
Gilead press release
HIV stigma decreases with scale-up of HIV treatment

In high-prevalence countries of sub-Saharan Africa, the scale-up of HIV treatment appears to have resulted in a lessening of stigmatising attitudes in the general population, according to

Published
30 June 2015
By
Roger Pebody
New British guidelines recommend treatment for everyone with HIV

Everyone with HIV who is prepared to take antiretroviral treatment should receive it, regardless of CD4 cell count, new draft British HIV Association (BHIVA) treatment guidelines

Published
24 June 2015
By
Keith Alcorn
Risks vs rewards: why people with HIV volunteer for 'cure' research

A recent survey of people living with HIV in the United Kingdom found that more than half would participate in a clinical study to develop a cure for HIV, despite this posing a risk to their health. Why would someone choose to do this?

Published
24 June 2015
From
The Conversation
Not having enough food linked to poor treatment outcomes in New York

People who don’t have enough food to eat are less likely to have an undetectable viral load than other people living with HIV, according to a longitudinal

Published
23 June 2015
By
Roger Pebody
← First12345...390Next →

Filter by country